title: Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
abstract: MF59 is already known to enhance the breadth of antibody response to mismatched influenza seasonal and avian strains. However, little is known on the effect of MF59 on immunogenicity of influenza vaccines when "apparent" good matching between circulating and vaccine strains exists. To this end, we compared the immune response elicited by MF59-adjuvanted or non-adjuvanted subunit vaccine, containing A/California/7/04(H3N2) strain, against circulating viruses isolated between 2004/2005 and 2006/2007 seasons, belonging to different clades. The advantage offered by MF59 in terms of higher immunogenicity, expressed as higher post-vaccination HI titres, is observable also against viruses showing antigenic and molecular pattern undistinguishable from vaccine strain, but it became even more evident as the antigenic and molecular distance between vaccine and circulating strains grew. These data show that seasonal influenza vaccine adjuvanted with MF59 can offer a stronger benefit as compared to non-adjuvanted vaccine in protecting against a broader range of virus strains circulating during the influenza season.
authors.affiliation: CIRI-IV, Department of Health Sciences, University of Genoa, Via Pastore 1, 16100 Genoa, Italy. filippo.ansaldi@unige.it
authors.forename: Filippo
authors.initials: F
authors.lastname: Ansaldi
authors.forename: Marta
authors.initials: M
authors.lastname: Zancolli
authors.forename: Paolo
authors.initials: P
authors.lastname: Durando
authors.forename: Emanuele
authors.initials: E
authors.lastname: Montomoli
authors.forename: Laura
authors.initials: L
authors.lastname: Sticchi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Del Giudice
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Icardi
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D056738:Cross Protection; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D011136:Polysorbates / Q000494:pharmacology*; D013185:Squalene / Q000494:pharmacology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D013185:Squalene